Henning Kramer is an accomplished professional with a strong background in pharmacology and drug development. At The Janssen Pharmaceutical Companies of Johnson & Johnson from May 2020 to March 2023, Henning served as the Director of the CVRM & PH Therapeutic Area, leading a team focused on preclinical infrastructure for non-alcoholic steatohepatitis (NASH) and identifying novel targets informed by human genetics and clinical insights. Currently, Henning holds the position of Executive Director for Diabetes, Obesity and Complications at Eli Lilly and Company since April 2023. Prior experience includes roles as a Principal Scientist and Director in muscle metabolism at GSK, where Henning led preclinical programs for muscular dystrophy therapies, and as a Scientific Director at The Joslin Diabetes Center. Henning holds a Bachelor of Science in Kinesiology and Exercise Science from the University of Maryland College Park and a Ph.D. in Physiology from Penn State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices